Protocol Ledger

NCT04221477 · Phase III · ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis

Interventional Phase III clinical trial protocol NCT04221477 sponsored by Roche / Genentech in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-08-10 Enrollment: 271 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04221477
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)271 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04221477
Protocol FieldVerified Registry Value
NCT IdentifierNCT04221477
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment271 participants (ACTUAL)
Registered Start Date2020-08-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04221477
Hospital Research SiteLocationSite Profile
Kaiser Permanente-FontanaFontana, CAOpen Hospital Dossier ->
Stanford Health Care and Stanford Cancer InstituteStanford, CAOpen Hospital Dossier ->
Yale Cancer Center and Smilow Cancer HospitalNew Haven, CTOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI